Skip to main content

Research Repository

Advanced Search

All Outputs (77)

COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study (2021)
Journal Article
Allsup, D., Howard, D., Emmerson, J., Hockaday, A., Rawstron, A., Oughton, J. B., Bloor, A., Phillips, D., Nathwani, A., Paneesha, S., Turner, D., Munir, T., & Hillmen, P. (in press). COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British journal of haematology, https://doi.org/10.1111/bjh.17526

Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia (2021)
Journal Article
Molica, S., Allsup, D., Gianfelici, V., Levato, L., Aiello, V., Bailey, J., & Polliack, A. (in press). Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs, https://doi.org/10.1080/13543784.2021.1924669

Introduction: Venetoclax has emerged as a breakthrough treatment which has revolutionized the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed to the efficacy of venetoclax as a time-limited, chemo-free, therap... Read More about Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.

Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia (2021)
Journal Article
Lin, W. Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., Willmore, E., Shepherd, C., Strathdee, G., Mainou-Fowler, T., Piddock, R., Mearns, H., Barrow, T., Houlston, R. S., Marr, H., Wallis, J., Summerfield, G., Marshall, S., Pettitt, A., Pepper, C., Fegan, C., …Allan, J. M. (2021). Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. Nature communications, 12(1), Article 665. https://doi.org/10.1038/s41467-020-20822-9

© 2021, The Author(s). Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects disease progression and could aid prognost... Read More about Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.

Whole-genome sequencing of a sporadic primary immunodeficiency cohort (2020)
Journal Article
Cooper, N., Abbs, S., Farmery, J. H., Deevi, S. V., Thaventhiran, J. E., Adhya, Z., Adlard, J., Afzal, M., Ahmed, I., Ahmed, M., Ahmed, S., Aitman, T. J., Alachkar, H., Anderson, J., Alamelu, J., Alikhan, R., Allen, C. E., Allen, L., Alvi, A., Ambegaonkar, G., …Smith, K. G. C. (2020). Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 583(7814), 90-95. https://doi.org/10.1038/s41586-020-2265-1

Primary immunodeficiency (PID) is characterized by recurrent and often life-threatening infections, autoimmunity and cancer, and it poses major diagnostic and therapeutic challenges. Although the most severe forms of PID are identified in early child... Read More about Whole-genome sequencing of a sporadic primary immunodeficiency cohort.

Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints (2020)
Journal Article
Chester, R., Das, A. A. K., Medlock, J., Nees, D., Allsup, D. J., Madden, L. A., & Paunov, V. N. (2020). Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints. ACS Applied Bio Materials, 3(2), 789-800. https://doi.org/10.1021/acsabm.9b00770

We report a cell recognition chromatography approach for blood cancer cell separation from healthy peripheral blood mononuclear cells (PBMCs) based on sizematched functionalized particle imprints. Negative imprints were prepared from layers of 15 μm... Read More about Removal of Human Leukemic Cells from Peripheral Blood Mononuclear Cells by Cell Recognition Chromatography with Size Matched Particle Imprints.

Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints (2019)
Journal Article
Das, A. A., Remaud, P., Medlock, J., Das, A. A. K., Allsup, D. J., Madden, L. A., Nees, D., Weldrick, P. J., & Paunov, V. N. (2019). Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints. Materials Chemistry Frontiers, 4(1), 197-205. https://doi.org/10.1039/c9qm00531e

We report a new approach for separation of blood cancer cells from healthy white blood cells based on cell recognition by surface functionalised particle imprints. We prepared polymeric particle imprints from a layer of suspension of monodisperse PMM... Read More about Targeted removal of blood cancer cells from mixed cell populations by cell recognition with matching particle imprints.

Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants (2019)
Journal Article
Bury, L., Megy, K., Stephens, J. C., Grassi, L., Greene, D., Gleadall, N., Althaus, K., Allsup, D., Bariana, T. K., Bonduel, M., Butta, N. V., Collins, P., Curry, N., Deevi, S. V., Downes, K., Duarte, D., Elliott, K., Falcinelli, E., Furie, B., Keeling, D., …Westbury, S. K. (2020). Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Human Mutation, 41(1), 277-290. https://doi.org/10.1002/humu.23927

Human Mutation published by Wiley Periodicals, Inc. The heterogeneous manifestations of MYH9-related disorder (MYH9-RD), characterized by macrothrombocytopenia, Döhle-like inclusion bodies in leukocytes, bleeding of variable severity with, in some ca... Read More about Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants.

Germline selection shapes human mitochondrial DNA diversity (2019)
Journal Article
Wei, W., Tuna, S., Keogh, M. J., Smith, K. R., Aitman, T. J., Beales, P. L., Bennett, D. L., Gale, D. P., Bitner, M. A. K., Ashford, S., Penkett, C. J., Stirrups, K. E., Rendon, A., Ouwehand, W. H., Bradley, J. R., Raymond, L., Caulfield, M., Turro, E., & Chinnery, P. F. (2019). Germline selection shapes human mitochondrial DNA diversity. Science, 364(6442), Article eaau6520. https://doi.org/10.1126/science.aau6520

INTRODUCTION
Only 2.4% of the 16.5-kb mitochondrial DNA (mtDNA) genome shows homoplasmic variation at >1% frequency in humans. Migration patterns have contributed to geographic differences in the frequency of common genetic variants, but population... Read More about Germline selection shapes human mitochondrial DNA diversity.

Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood (2019)
Journal Article
Das, A. A., Medlock, J., Liang, H., Nees, D., Allsup, D. J., Madden, L. A., & Paunov, V. N. (2019). Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood. Journal of Materials Chemistry B, 7(22), 3497-3504. https://doi.org/10.1039/c9tb00679f

We report a large scale preparation of bioimprints of layers of cultured human leukemic HL60 cells which can perform cell shape and size recognition from a mixture with peripheral blood mononuclear cells (PBMCs). We demonstrate that the bioimprint-ce... Read More about Bioimprint aided cell recognition and depletion of human leukemic HL60 cells from peripheral blood.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology (2018)
Journal Article
Went, M., Sud, A., Speedy, H., Sunter, N. J., Försti, A., Law, P. J., Johnson, D. C., Mirabella, F., Holroyd, A., Li, N., Orlando, G., Weinhold, N., van Duin, M., Chen, B., Mitchell, J. S., Mansouri, L., Juliusson, G., Smedby, K. E., Jayne, S., Majid, A., …Houlston, R. S. (2019). Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal, 9(1), Article 1. https://doi.org/10.1038/s41408-018-0162-8

© 2018, The Author(s). The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) a... Read More about Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia (2018)
Journal Article
Turro, E., Bariana, T. K., Gomez, K., Labarque, V., Heremans, J., Whitehorn, D., Thys, C., NIHR BioResource, De Reys, M., Freson, K., Greene, D., Frontini, M., Jenkins, B., Ghevaert, C., Grassi, L., Ouwehand, W. H., Seyres, D., Koulman, A., Burden, F., Van Geet, C., …Shamardina, O. (2018). Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia. Haematologica, 104(4), haematol.2018.204784. https://doi.org/10.3324/haematol.2018.204784

Sphingolipids are fundamental to membrane trafficking, apoptosis and cell differentiation and proliferation. KDSR or 3-keto-dihydrosphingosine reductase is an essential enzyme for de novo sphingolipid synthesis, and pathogenic mutations in KDSR resul... Read More about Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia.

A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia (2018)
Journal Article
Johnson, B., Doak, R., Allsup, D., Astwood, E., Evans, G., Grimley, C., James, B., Myers, B., Stokley, S., Thachil, J., Wilde, J., Williams, M., Makris, M., Lowe, G. C., Wallis, Y., Daly, M. E., Morgan, N. V., & the UK GAPP Study Group. (2018). A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia. Research and Practice in Thrombosis and Haemostasis, 2(4), 640-652. https://doi.org/10.1002/rth2.12151

Background: Inherited thrombocytopenias (ITs) are a heterogeneous group of disorders characterized by low platelet counts and often disproportionate bleeding with over 30 genes currently implicated. Previously the UK-GAPP study using whole exome sequ... Read More about A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia.

Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome (2017)
Journal Article
Till, K. J., Allen, J. C., Talab, F., Lin, K., Allsup, D., Cawkwell, L., Bentley, A., Ringshausen, I., Duckworth, A. D., Pettitt, A. R., Kalakonda, N., & Slupsky, J. R. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. Scientific reports, 7(1), Article ARTN 16784. https://doi.org/10.1038/s41598-017-17021-w

© 2017 The Author(s). Pathogenesis of chronic lymphocytic leukaemia (CLL) is contingent upon antigen receptor (BCR) expressed by malignant cells of this disease. Studies on somatic hypermutation of the antigen binding region, receptor expression leve... Read More about Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome.

Hematological malignancies in pregnancy (2017)
Book Chapter
Allsup, D., Ali, S., & Robinson, S. (2017). Hematological malignancies in pregnancy. In D. James, P. Steer, C. Weiner, B. Gonik, & S. Robson (Eds.), High-Risk Pregnancy: Management Options (1006-1043). Cambridge University Press

The diagnosis of a hematological malignancy during pregnancy poses a major challenge to the pregnant woman, her family, and the medical team. Treatment of a pregnant woman with chemotherapy poses a risk to the fetus and raises therapeutic, ethical, a... Read More about Hematological malignancies in pregnancy.

The use of ofatumumab in the treatment of B-cell malignancies (2017)
Journal Article
Soe, Z. N., & Allsup, D. (2017). The use of ofatumumab in the treatment of B-cell malignancies. Future oncology, 13(29), 2611-2628. https://doi.org/10.2217/fon-2017-0275

Ofatumumab has been extensively studied in the treatment of B-cell malignancies. Currently, it has been approved for the treatment of chronic lymphocytic leukemia in a number of different situations. However, there is still no compelling evidence con... Read More about The use of ofatumumab in the treatment of B-cell malignancies.

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial (2017)
Journal Article
Collett, L., Howard, D. R., Munir, T., McParland, L., Oughton, J. B., Rawstron, A. C., Hockaday, A., Dimbleby, C., Phillips, D., McMahon, K., Hulme, C., Allsup, D., Bloor, A., & Hillmen, P. (2017). Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials, 18(1), Article 387. https://doi.org/10.1186/s13063-017-2138-6

Background
Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. How... Read More about Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

Cancer bioimprinting and cell shape recognition for diagnosis and targeted treatment (2017)
Journal Article
Medlock, J., Das, A. A. K., Madden, L. A., Allsup, D. J., & Paunov, V. N. (2017). Cancer bioimprinting and cell shape recognition for diagnosis and targeted treatment. Chemical Society Reviews, 46(16), 5110-5127. https://doi.org/10.1039/c7cs00179g

Cancer incidence and mortality have both increased in the last decade and are predicted to continue to rise. Diagnosis and treatment of cancers are often hampered by the inability to specifically target neoplastic cells. Bioimprinting is a promising... Read More about Cancer bioimprinting and cell shape recognition for diagnosis and targeted treatment.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma (2017)
Journal Article
Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P., & Stankovic, T. (2018). A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. British journal of haematology, 182(3), 429-433. https://doi.org/10.1111/bjh.14793

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL (2017)
Journal Article
Howard, D. R., Munir, T., McParland, L., Rawstron, A. C., Milligan, D., Schuh, A., Hockaday, A., Allsup, D. J., Marshall, S., Duncombe, A. S., O'Dwyer, J. L., Smith, A. F., Longo, R., Varghese, A., & Hillmen, P. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 31(11), 2416-2425. https://doi.org/10.1038/leu.2017.96

© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontli... Read More about Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.